Supplementation with a Soluble Dietary Fiber, NUTRIOSE®, Improves Insulin Resistance and Determinants of Metabolic Syndrome in Overweight Men

Authors

C. LEFRANC-MILLOT, Roquette, Lestrem, France  

S. LI, Institute of Nutrition, Health and Food, Tongi University Medical College, Shanghai, China 

L. GUERIN-DEREMAUX, Roquette, Lestrem, France  

M. POCHAT, Roquette, Lestrem, France  

D. WILS, Roquette, Lestrem, France  

C. REIFER, SPRIM Advanced Life Science, San Francisco, CA, USA 

L. MILLER, SPRIM Advanced Life Science, San Francisco, CA, USA 

INTRODUCTION

How dietary fiber can influence determinants of metabolic syndrome is controversial. NUTRIOSE® (Roquette, France), a soluble resistant dextrin with prebiotic properties, has been clinically proven (34g/day) to beneficially affect body weight(BW), body mass index (BMI), body fat (BF), hunger feeling (HF) and caloric intake (CI)(1) (2). In this context, a secondary objective of the same trial was to investigate whether dietary supplementation with this fiber was associated with a positive impact on parameters such as insulin resistance and determinants of metabolic syndrome (MS) in overweight men, following a double-blind, randomized, placebo-controlled design.

MATERIALS AND METHODS

Objective

• To determine the effects of NUTRIOSE® supplementation on insulin resistance and the determinants of metabolic syndrome in overweight men.

Parameters

• Biomarkers of lipid metabolism: cholesterol (total, HDL, LDL, VLDL), triglycerides 
• Biomarkers of glucose metabolism: Adiponectin, glucose, insulin, glycosylated hemoglobin (HbA1c), glycated albumin after an overnight fast of 12h, at Week 0, 4, 8, 12
  
  
  

Product description

• Placebo: 250 ml Orange juice with 17g of maltodextrin ➜2 daily intakes = 34g/day 
• Treatment: 250 ml Orange juice with 17g of NUTRIOSE® ➜2 daily intakes = 34g/day

Study design

• Randomized, placebo-controlled, double blind, parallel, multi-center
• Groups: 2 groups of n=60 volunteers 
• Subjects: Overweight Chinese male adults aged 20-35 yrs, BMI=24-28 kg/m2

RESULTS

• Lipid metabolism: In the NUTRIOSE® group, there are decreases in the plasmatic concentrations of total-cholesterol (p<0.01), and an increase in HDL-cholesterol (p<0.01), these changes are significantly different from those observed in the placebo group. The VLDL-cholesterol (data not shown) and the triglycerides concentrations decrease also in the NUTRIOSE® group (p<0.01) but these changes are not different from those observed in the placebo group.
• Glucose metabolism: Subjects supplemented with NUTRIOSE® display significant reductions in plasmatic concentrations of glucose (p<0.001) and insulin (data not shown) although these changes are not significantly different from those observed with the placebo. HOMA-estimated insulin resistance exhibited a 18% decrease in the NUTRIOSE® group, greater than in the Placebo group (p=0.04) (data not shown) (3). Intermediate and long-term glucose control, measured by glycated albumin and glycosylated hemoglobin, improve over time in the NUTRIOSE® group (data not shown). Adiponectin, a cytokine which regulates glucose metabolism and stimulates fatty acid oxidation, increases in the NUTRIOSE® group (p<0.01) (data not shown).
• Biomarkers of the MS: The table 1 details, for each biomarker, the percentage of volunteers who experienced a 5% improvement between the beginning and the end of the study in each group. It shows that NUTRIOSE® largely improves the biological parameters involved in the MS.
• Prevalence of the MS: The prevalence of the MS after the 12-week supplementation period decreased in NUTRIOSE® subjects (from 27 to 12%) and increased in Placebo subjects (from 17 to 27%) (data not shown). In general, test subjects who presented MS at the beginning of the study had greater improvements in glucose metabolism markers than healthy subjects. No adverse events or gastrointestinal complaints, such as gas, bloating, or diarrhea, were reported in either group during the trial.

CONCLUSIONS

Twice daily supplementation with NUTRIOSE® over a 12-week period had been demonstrated (1) to significantly decrease BW, BMI, BF, WC and HF, in association with a decreased CI. Moreover, NUTRIOSE® has improved the lipid and glucose metabolisms of slightly overweight Chinese volunteers. The metabolic syndrome status of the volunteers is largely improved with NUTRIOSE®. Supplementation is well tolerated, lowers insulin resistance, and improves some determinants of metabolic syndrome in overweight men. This makes of NUTRIOSE® a promising tool for diet fortification with fibers, particularly in the context of weight management and chronic metabolic disorders associated with overweight (3).

LIST OF REFERENCES

(1) LEFRANC-MILLOT C, GUERIN-DEREMAUX L, WILS D, POCHAT M, LI S Effects of a soluble dietary fiber supplementation with NUTRIOSE® on risk factors of the metabolic syndrome in Chinese male adults. Obesity Reviews, 2010, 11(Suppl. 1): p. 438 

(2) GUERIN-DEREMAUX L, LI S, POCHAT M, WILS D, MUBASHER M, REIFER C and MILLER LE Effects of NUTRIOSE dietary fiber supplementation on body weight, body composition, energy intake, and hunger in overweight men. International Journal of Food Sciences and Nutrition, 2011 (in press)  

(3) LI S, GUERIN-DEREMAUX L, POCHAT M, WILS D, REIFER C, MILLER LE NUTRIOSE® Dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebocontrolled study. Applied Physiology, Nutrition and Metabolism, 2010, 35: 773–782 

DISCLAIMER

 Scientific data and other information contained or referred to herein is proprietary to Roquette Frères (Roquette). Roquette expressly reserves its exclusive right to refer to such data and other proprietary information for all purposes, including, but not limited to, for submitting dossiers pursuant to Regulation (EC) N° 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. 

The information contained in this document is to the best of our knowledge true and accurate, but all instructions, recommendations or suggestions are made without guarantee. Since the conditions of use are beyond our control, we disclaim any liability for loss and/or damage suffered from use of these data or suggestions. Furthermore, no liability is accepted if use of any product in accordance with these data or suggestions infringes any patent. No part of this document may be reproduced by any process without our prior written permission.  

© Roquette Frères S.A. - 03/11 - 4th International Congress on Prediabetes and the Metabolic Syndrome - Madrid (Spain), 06-09 April, 2011.